Related Experiment Videos
The endothelin system in cardiovascular physiology and pathophysiology
1Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Scotland, UK.
Insights
Endothelin-1 is a potent vasoconstrictor crucial for vascular tone and blood pressure. This peptide is implicated in cardiovascular diseases, highlighting the endothelin system as a therapeutic target.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor derived from the endothelium.
- ET-1 influences coronary, renal, and cerebral circulations and plays a role in fetal development.
- ET-1 is vital for regulating vascular tone and blood pressure in healthy individuals.
Purpose of the Study:
- To review the physiological role of Endothelin-1.
- To explore the involvement of Endothelin-1 in cardiovascular diseases.
- To discuss the therapeutic potential of targeting the endothelin system.
Main Methods:
- Literature review of studies on Endothelin-1.
- Analysis of Endothelin-1's effects on various circulatory systems.
- Examination of Endothelin-1's role in disease pathogenesis.
Main Results:
- Endothelin-1 causes sustained vasoconstriction and affects multiple circulations.
- ET-1 is essential for normal development and blood pressure regulation.
- Evidence links ET-1 to chronic heart failure, vasospasm, and atherosclerosis, acting against nitric oxide.
Conclusions:
- The endothelin system is a key mediator in cardiovascular diseases.
- Endothelin receptor antagonists are under clinical investigation.
- Targeting the endothelin system presents a promising therapeutic strategy for cardiovascular conditions.
Abstract:
Endothelin-1, a member of a novel family of regulatory peptides, is the most potent vasoconstrictor and pressor substance known. Endothelin-1 is a 21-amino-acid endothelium-derived peptide causing uniquely sustained vasoconstriction. In addition, endothelin-1 has pronounced effects on the coronary, renal and cerebral circulations, enhances responses to other vasoconstrictors, and is comitogenic. Recent studies have shown that the endothelins are essential for normal fetal development, and that endothelin-1 plays an important physiological role in the regulation of basal vascular tone and blood pressure in healthy humans. There is now also a wealth of evidence suggesting that endothelin-1 is a key mediator in a range of cardiovascular diseases associated with sustained vasoconstriction, such as chronic heart failure, and with vasospasm, such as subarachnoid haemorrhage. In addition, endothelin-1 appears to act in opposition to nitric oxide to promote the atherosclerotic process. There are a large number of oral and intravenously active endothelin antagonists entering clinical development and a number of clinical studies, particularly with endothelin receptor antagonists, are now under way. Such studies are beginning to define the role of the endothelins in cardiovascular disease and to confirm the potential of the endothelin system as an important new therapeutic target.